Get the Stockscreener App
38.19
5.85%
2.11
After Hours:
38.19
Springworks Therapeutics Inc stock is traded at $38.19, with a volume of 989.23K.
It is up +5.85% in the last 24 hours and down -10.25% over the past month.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
See More
Previous Close:
$36.08
Open:
$36.11
24h Volume:
989.23K
Relative Volume:
0.92
Market Cap:
$2.84B
Revenue:
-
Net Income/Loss:
$-275.16M
P/E Ratio:
-9.8175
EPS:
-3.89
Net Cash Flow:
$-221.15M
1W Performance:
+5.06%
1M Performance:
-10.25%
6M Performance:
+2.44%
1Y Performance:
-0.96%
1-Day Range:
$36.11
$38.57
1-Week Range:
$35.39
$38.57
52-Week Range:
$28.21
$53.92
Springworks Therapeutics Inc Stock (SWTX) Company Profile
Name
Springworks Therapeutics Inc
Sector
Industry
Phone
203-883-9490
Address
100 WASHINGTON BOULEVARD, STAMFORD, CT
Compare SWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SWTX
Springworks Therapeutics Inc
|
38.19 | 2.84B | 0 | -275.16M | -221.15M | -3.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
Springworks Therapeutics Inc Stock (SWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Initiated | Evercore ISI | Outperform |
| Feb-05-24 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
| Jan-19-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| Mar-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-04-19 | Initiated | H.C. Wainwright | Buy |
| Oct-08-19 | Initiated | Cowen | Outperform |
| Oct-08-19 | Initiated | Goldman | Buy |
| Oct-08-19 | Initiated | JP Morgan | Overweight |
| Oct-08-19 | Initiated | Wedbush | Outperform |
View All
Springworks Therapeutics Inc Stock (SWTX) Latest News
SpringWorks Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great - Seeking Alpha
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives $69.50 Consensus Target Price from Brokerages - Defense World
How To Trade (SWTX) - Stock Traders Daily
Ethanol Futures (ZKZ25) Quote - The Globe and Mail
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Principal Financial Group Inc. Has $29.43 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Stifel Financial Corp Reduces Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
Low Grade Glioma Market Predicted to See Upsurge Through 2034, - openPR
Geode Capital Management LLC Has $53.53 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Barclays PLC Raises Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
(SWTX) On The My Stocks Page - Stock Traders Daily
Comparing Titan Pharmaceuticals (NASDAQ:TTNP) & SpringWorks Therapeutics (NASDAQ:SWTX) - Defense World
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm - GuruFocus.com
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
SpringWorks Therapeutics' SWOT analysis: stock potential amid clinical progress By Investing.com - Investing.com South Africa
SpringWorks Therapeutics' SWOT analysis: stock potential amid clinical progress - Investing.com India
Lord Abbett & CO. LLC Has $34.27 Million Stock Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $3.20 Million Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue? - MSN
Main Management ETF Advisors LLC Buys Shares of 23,280 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Charles Schwab Investment Management Inc. Raises Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
(SWTX) Trading Report - Stock Traders Daily
Soros Fund Management LLC Acquires 174,321 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Insider Sell Alert: Badreddin Edris Sells 20,000 Shares of SpringWorks Therapeutics Inc (SWTX) - GuruFocus.com
Springworks Therapeutics COO sells $839,335 in stock By Investing.com - Investing.com UK
Erste Asset Management GmbH Takes Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Springworks Therapeutics CEO Islam Saqib sells $2 million in stock - Investing.com
Springworks Therapeutics CEO Islam Saqib sells $2 million in stock By Investing.com - Investing.com Nigeria
Saqib Islam Sells 49,000 Shares of SpringWorks Therapeutics Inc (SWTX) - GuruFocus.com
High Growth Tech Stocks to Watch in December 2024 - Simply Wall St
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Position Boosted by The Manufacturers Life Insurance Company - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by HighVista Strategies LLC - MarketBeat
Are Investors Eager To Sell Holdings In SpringWorks Therapeutics Inc (NASDAQ: SWTX)? - Stocks Register
Walleye Capital LLC Boosts Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Fmr LLC Boosts Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Intech Investment Management LLC Invests $676,000 in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Dynamic Technology Lab Private Ltd Buys Shares of 13,717 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Ally Bridge Group NY LLC Invests $7.30 Million in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
SpringWorks Therapeutics to Present at Evercore ISI HealthCONx Conference | SWTX Stock News - StockTitan
Massachusetts Financial Services Co. MA Boosts Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
(SWTX) Investment Analysis - Stock Traders Daily
SpringWorks Therapeutics' SWOT analysis: stock shows promise amid challenges - Investing.com
Alpha DNA Investment Management LLC Makes New $411,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
GSA Capital Partners LLP Makes New $209,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
Vertex leads J.P. Morgan's top biotech picks list for 2025 (NASDAQ:VRTX) - Seeking Alpha
Eagle Asset Management Inc. Sells 54,366 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - MarketBeat
Springworks Therapeutics Inc Stock (SWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
2.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):